Advanced Biomed (ADVB) Fundamental Analysis: Revenue, Earnings & Valuation

0.40 / 10

Underperform

Fundamental rating is Underperform with a 0.4 score. Asset‑MV and Profit‑MV show modest strength, but cash metrics, ROE, ROA and profit margins are deeply negative, placing the company in low‑quality quartiles. Overall, the fundamentals are weak and constrain valuation.

Analysis Checks(3/10)

ROA (%)

Value-59.40

Score1/3

Weight19.00%

1M Return-1.19%

Annualized return on equity (%)

Value-126.79

Score1/3

Weight31.46%

1M Return-2.02%

Profit-MV

Value3.31

Score2/3

Weight-63.48%

1M Return3.26%

Cash-UP

Value-0.16

Score2/3

Weight57.90%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-59.40

Score1/3

Weight19.00%

1M Return-1.19%

ROE (diluted) (%)

Value-93.71

Score1/3

Weight22.05%

1M Return-1.41%

Asset-MV

Value-0.55

Score3/3

Weight-102.44%

1M Return4.79%

ROE (%)

Value-126.79

Score1/3

Weight31.46%

1M Return-2.02%

Cash-MV

Value0.03

Score1/3

Weight49.91%

1M Return-3.56%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight35.13%

1M Return-2.37%

Is ADVB undervalued or overvalued?

ADVB scores 0.40/10 on fundamentals and holds a Premium valuation at present. Backed by its 99.87% ROE, 0.00% net margin, 1.33 P/E ratio, 0.62 P/B ratio, and 4033.33% earnings growth, these metrics solidify its Underperform investment rating.